Skip to content
value.today
Adimab, LLC logo

Adimab, LLC

Total raised
$14 M
1 round on record
Latest round
$14 M
Mar 2012
First round on record
Mar 2012
Today
Private
No later event on record

Funding rounds

1 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of Adimab, LLC
MonthRaisedRaiseSizeInvestorsSoldFiling
Mar 2012$14 MNo. 1$10 to $50 million

Adimab, LLC: Raise no. 1, Mar 2012

Investors in this round

12 investors had bought by the notice of Apr 2, 2012: 12 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$14 M of $14 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Limited Liability Company, incorporated in Delaware

People named in the notice

  • Errik B. Anderson · Executive Officer, Director
  • Robert L. Birnbaum · Executive Officer
  • Tillman U. Gerngross · Executive Officer, Director
  • Fran J. Heller · Director
  • Michael J. Ross · Director
  • Terrance L. McGuire · Director
  • William J. Maris · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Robert L. Birnbaum, Corporate Secretary. Source: SEC Form D, newest notice filed Apr 2, 2012. Read the notice at the SEC.

equitySEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Adimab, LLC chose not to state its revenue in its newest notice of a funding round (Apr 2012).

    SEC Form D · Apr 2012

  • The industry group it chose in its notices: Biotechnology.

    SEC Form D · Apr 2012

That is all the official record says: Adimab, LLC has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.

In its own words

How the company describes itself to search engines on its website, word for word.

“Adimab is a biotechnology company specializing in the discovery and optimization of fully human antibodies for therapeutic development.”

Source: The company's website · as of Nov 15, 2026

Products and services#

No products or services on record: its website does not describe any in structured form (a page that declares itself a product or service), and Wikidata lists none.

Investors#

No investor of Adimab, LLC is named in an official source we use. Its funding notices give only how many investors bought, not who they are.

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 1 round above had up to 12 investors.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Adimab, LLC
NameRoleNamed in
Errik B. AndersonExecutive officerApr 2012
Robert L. BirnbaumExecutive officerApr 2012
Tillman U. GerngrossExecutive officerApr 2012
Errik B. AndersonDirectorApr 2012
Fran J. HellerDirectorApr 2012
Michael J. RossDirectorApr 2012
Terrance L. McGuireDirectorApr 2012
Tillman U. GerngrossDirectorApr 2012
William J. MarisDirectorApr 2012

About

Organization.